Biogen Reports Additional Results From Phase 3 Pediatric Studies

(RTTNews) - Biogen Idec (BIIB), along with Swedish Orphan Biovitrum AB (STO:SOBI) Monday announced additional results from Phase 3 studies of their investigational drug indicates for the treatment of hemophilia B and A.

These interim data demonstrated that ALPROLIX and ELOCTATE have consistently prolonged half-lives in children, compared to study participants' prior therapies.

ALPROLIX and ELOCTATE use a technology called Fc fusion and demonstrate prolonged circulation in the body, which has been shown in studies of adults with hemophilia to extend the time between prophylactic infusions.

The company is currently investigating whether prophylactic dosing intervals longer than the currently available therapy are possible with these treatments.

"The frequency of traditional prophylactic regimens is a significant challenge for parents of children with hemophilia, many of whom require infusions multiple times per week." said Guy Young, M.D., director, Hemostasis and Thrombosis Center, Children's Hospital Los Angeles.